Adaptimmune Therapeutics Plc ADR (ADAP)’s price-to-cash and price-to-free cash flow ratios

The price of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $1.33 in the last session, up 13.68% from day before closing price of $1.17. In other words, the price has increased by $+0.1600 from its previous closing price. On the day, 3009590 shares were traded. ADAP stock price reached its highest trading level at $1.3700 during the session, while it also had its lowest trading level at $1.1300.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.


We take a closer look at ADAP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.92 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.23.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bryan Garnier on March 24, 2023, initiated with a Buy rating and assigned the stock a target price of $3.60.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 17 when Rawcliffe Adrian sold 30,080 shares for $0.67 per share. The transaction valued at 20,244 led to the insider holds 44,848 shares of the business.

Bertrand William C JR sold 18,908 shares of ADAP for $12,725 on Jan 17. The Chief Operating Officer now owns 7,785 shares after completing the transaction at $0.67 per share. On Jan 17, another insider, Norry Elliot, who serves as the Chief Medical Officer of the company, sold 18,276 shares for $0.67 each. As a result, the insider received 12,300 and left with 7,785 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 302.07M and an Enterprise Value of 165.94M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.22 while its Price-to-Book (P/B) ratio in mrq is 3.42. Its current Enterprise Value per Revenue stands at 2.33 whereas that against EBITDA is -1.58.

Stock Price History:

Over the past 52 weeks, ADAP has reached a high of $1.85, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is 0.6735, while the 200-Day Moving Average is calculated to be 0.8383.

Shares Statistics:

According to the various share statistics, ADAP traded on average about 1.18M shares per day over the past 3-months and 3.78M shares per day over the past 10 days. A total of 226.93M shares are outstanding, with a floating share count of 196.86M. Insiders hold about 13.25% of the company’s shares, while institutions hold 60.11% stake in the company. Shares short for ADAP as of Jan 11, 2024 were 5.77M with a Short Ratio of 5.77M, compared to 6.12M on Dec 14, 2023. Therefore, it implies a Short% of Shares Outstanding of 2.54% and a Short% of Float of 5.36%.

Earnings Estimates

The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of $0 and a low estimate of -$0.17, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.15.

Analysts are recommending an EPS of between -$0.33 and -$0.52 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.49, with 4 analysts recommending between -$0.4 and -$0.6.

Revenue Estimates

According to 6 analysts, the current quarter’s revenue is expected to be $20.47M. It ranges from a high estimate of $39M to a low estimate of $2M. As of the current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $11.03M, an estimated increase of 85.60% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $10.52M, a decrease of -77.90% less than the figure of $85.60% in the same quarter last year. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.

A total of 6 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $99.1M, while the lowest revenue estimate was $62M, resulting in an average revenue estimate of $80.54M. In the same quarter a year ago, actual revenue was $27.15M, up 196.70% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $44.11M in the next fiscal year. The high estimate is $75M and the low estimate is $22.8M. The average revenue growth estimate for next year is down -45.20% from the average revenue estimate for this year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular